- |||||||||| Soliris (eculizumab) / AstraZeneca
When the Eyes Become the Window for the Kidneys: A Case of Rapidly Progressive C3 Glomerulonephritis (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_2372; In addition to nonspecific therapy for proteinuria, MMF plus steroids or eculizumab alone may be considered based on the severity of proteinuria and degree of renal fibrosis. Additional studies are needed to establish if rapidly progressive cases are treatment responsive or have a higher recurrence risk after kidney transplantation.
- |||||||||| Soliris (eculizumab) / AstraZeneca
Long-Term Outcomes in Eculizumab-Treated Patients Enrolled in the Global aHUS Registry (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_2355; P=N/A Conclusion In a real-world setting, eGFR was stable in most patients receiving ecu. Some patients demonstrated hematologic benefits but no renal response; they had lower BL eGFR and initiated treatment late.
- |||||||||| Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Renal Pathologies and Patient Outcomes Post Allogeneic Stem Cell Transplantation (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1993; Based on our center experience, switching GVHD prophylaxis from tacrolimus to sirolimus might improve renal outcome. Renal response to anticomplement therapy and rituximab was variable.
- |||||||||| Soliris (eculizumab) / AstraZeneca
Pancreatitis-Associated Atypical Hemolytic Uremic Syndrome (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1915; He was started on eculizumab and is continuing treatment with hopes of renal recovery although he is currently dialysis-dependent...This case highlights the association of aHUS with pancreatitis and demonstrates how lack of thrombocytopenia does not rule out HUS. Table 1: Notable lab values on admission
- |||||||||| Soliris (eculizumab) / AstraZeneca
Diarrheal Dilemma: A Unique Cause of Atypical Hemolytic Uremic Syndrome (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1903; Literature review of CD-aHUS cases showed that out of ten patients, six underwent plasmapheresis with three patients using eculizumab. This case report highlights the efficacy of plasmapheresis as a treatment modality for CD-aHUS.
- |||||||||| Promacta (eltrombopag) / Novartis
A Case of Eltrombopag-Associated Renal-Limited Thrombotic Microangiopathy (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1899; This had been managed with cessation of anticoagulation, rituximab, IVIG and eltrombopag (a thrombopoietin receptor agonist)...She was treated with corticosteroids and eculizumab and was initiated on hemodialysis...Awareness to the possibility of eltrombopag-associated TMA is important for patient safety in patients with worsening kidney function, especially in the setting of recent dose adjustments. Patients with APLS and ITP may be at higher risk.
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Obinutuzumab-Containing Multimodality Induction in Kidney Transplantation (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1662; Patients received eculizumab 900 mg prior graft reperfusion...As maintenance, we used LCP-tacrolimus (C0, 10-15 ng/mL), mycophenolate mofetil (MMF, 2000 mg/day), and prednisone...Also, obinutuzumab-induced B-cell depletion appears to be uneffected by concomitant complement inhibition. Such encouraging findings should prompt further investigation.
- |||||||||| Soliris (eculizumab) / AstraZeneca
Thrombotic Microangiopathy as a Presentation of Paroxysmal Nocturnal Hemoglobinuria and Lupus Nephritis (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1501; In our patient, we found a deficient CD59 pattern that can also be observed in SLE or hemolytic anemias. Therapeutics can be directed by targeting complement protein C5, eculizumab is a treatment option that has been shown to significantly reduce hemolysis and thus hemolysis-related side effects in PNH cases.
- |||||||||| Soliris (eculizumab) / AstraZeneca
Bamboozled: Concomitant Lupus Nephritis and Systemic Thrombotic Microangiopathy (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1498; Definitive data for cessation of eculizumab is not available, but cessation has not resulted in a recurrent flare. Despite a biopsy without typical characteristic full-house staining for LN, the patient responded well to the Euro-lupus protocol and remains with stable kidney function and minimal proteinuria.
- |||||||||| COVID-19 Vaccination as a Trigger for Atypical Hemolytic Uremic Syndrome (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_907;
We advise clear patient instruction and routinely monitoring of serum creatinine, proteinuria, mechanical hemolytic anemia (MAHA) parameters, and blood pressure approximately 3-7 days after COVID-19 vaccination in patients with a previous episode of aHUS, and/or a proven (likely) pathogenic variant in complement protein(s), and who are not treated with complement inhibitory therapy (eculizumab/ravulizumab). In addition, aHUS should be included in the differential diagnosis of patients with vaccine-induced thrombocytopenia, especially if co-occuring with MAKA and acute kidney injury.
- |||||||||| Soliris (eculizumab) / AstraZeneca
AKI due to Cocaine-Induced Thrombotic Microangiopathy (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_831; National Complement Centre recommended starting IV Eculizumab; pending further results...Discussion Cocaine use is associated with TMA although rarely reported & admitting physician need to be alert of this possibility. Table 1
- |||||||||| cemdisiran (ALN-CC5) / Alnylam, Regeneron, pozelimab (REGN3918) / Regeneron
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy (clinicaltrials.gov) - Oct 7, 2022 P2, N=6, Active, not recruiting, Further prospective research studies are recommended to improve the management and outcomes of TA-TMA. Recruiting --> Active, not recruiting | N=12 --> 6 | Trial completion date: Mar 2025 --> May 2024 | Trial primary completion date: Mar 2023 --> May 2022
- |||||||||| Voydeya (danicopan) / AstraZeneca, Soliris (eculizumab) / AstraZeneca, Ultomiris (ravulizumab-cwvz) / AstraZeneca
Enrollment closed, Trial primary completion date: Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA) (clinicaltrials.gov) - Oct 3, 2022 P3, N=86, Active, not recruiting, However, it should be considered as a potential alternative therapy because it may be associated with decreased DSA levels. Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2022 --> Jun 2022
- |||||||||| Soliris (eculizumab) / AstraZeneca
Journal: Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients. (Pubmed Central) - Sep 30, 2022 Eculizumab, a C5-inhibitor, is the only approved treatment for MG that mechanistically addresses complement-mediated loss of nicotinic acetylcholine receptors...To enable identification of MG patients that are likely to respond to C7 inhibition, we developed a patient stratification assay and showed in a small cohort of MG patients (n=19) that 63% had significant complement activation and C7-dependent loss of AChRs in this in vitro set up. This study provides validation of C7 as a target for treatment of MG and provides a means of identifying patients likely to respond to anti-C7 therapy based on complement-activating properties of patient autoantibodies.
- |||||||||| Soliris (eculizumab) / AstraZeneca, Empaveli (pegcetacoplan SC) / Apellis, SOBI
Review, Journal: With complements: C3 inhibition in the clinic. (Pubmed Central) - Sep 29, 2022 In this review, we compare the MoA of pegcetacoplan and eculizumab in paroxysmal nocturnal hemoglobinuria and discuss the complement-mediated disease that might be amenable to C3 inhibition. We further discuss the current state and outlook for C3-targeted therapeutics and provide our perspective on which diseases might be the next success stories in the C3 therapeutics journey.
- |||||||||| Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe, Soliris (eculizumab) / AstraZeneca, Enspryng (satralizumab) / Roche
Review, Journal: Immunobiology of neuromyelitis optica spectrum disorders. (Pubmed Central) - Sep 21, 2022 Acute relapses are treated with IV methylprednisolone or plasma exchange. Recent advances on the NMOSD immunobiology led to approved treatments such as eculizumab, satralizumab, and inebilizumab.
- |||||||||| Darzalex (daratumumab) / J&J, Soliris (eculizumab) / AstraZeneca, felzartamab (MOR202) / HIBio
Journal: Emerging strategies for antibody-mediated rejection. (Pubmed Central) - Sep 20, 2022 New drugs are available and transplant physicians are starting to develop effective multidrug strategies to counter the complex disease mechanisms. Safety of these drugs needs to be further explored especially when used together with other potent immunosuppressive drugs.
- |||||||||| Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab IV) / AstraZeneca
Atypical Hemolytic Uremic Syndrome : Safe switch from eculizumab to ravulizumab (Poster Area - Exhibition Hall E) - Sep 20, 2022 - Abstract #IPNA2022IPNA_545; Both complement inhibitors eculizumab and ravulizumab appear to be effective and safe in treating aHUS. Based on our experience, switching from eculizumab to ravulizumab seems to be well-tolerated in pediatric patients with aHUS, permitting reduction of dosing frequency, and therefore improvement of life quality.
- |||||||||| Soliris (eculizumab) / AstraZeneca
Experiences in Paediatric Nephrology services in a resource limited setting - tertiary care Centre in North Karnataka, India (Poster Area - Exhibition Hall E) - Sep 20, 2022 - Abstract #IPNA2022IPNA_525; Complement mediated diseases like HUS are being managed with limited options due to unavailability of Eculizumab resulting in prolonged hospital stay, morbidity and mortality. Majority of patients with CKD are managed conservatively without proceeding to continuous ambulatory peritoneal dialysis (CAPD) or chronic haemodialysis due to unavailability of the required resources .
- |||||||||| Soliris (eculizumab) / AstraZeneca
Relapsing atypical hemolytic uremic syndrome (Poster Area - Exhibition Hall E) - Sep 20, 2022 - Abstract #IPNA2022IPNA_521; To detect early relapse in aHUS, close monitoring of the patients is essential. In this particular disease, resuming eculizumab, higher eculizumab doses and/or shorter intervals to ensure an efficient and sustained blockade seem required.
|